关于亚洲范围内的患有真菌性蕁麻疹的(MF)患者的预后统计和数据很有限。本研究旨在确定中国患者中MF的预后因素和生存结局。该研究是对于在中国北京大学第一医院皮肤淋巴瘤专科接受治疗的MF患者的回顾性队列研究，数据从2009年8月1日至2021年8月31日收集，分析时间为2021年9月1日至2022年12月31日。通过Cox比例风险模型分析测定整体生存率(OS)，疾病特异性生存率(DSS)和无进展生存率(PFS)作为预后因素的危险比(HRs)和经过调整的危险比(aHRs) (根据性别，年龄和总体TNMB [肿瘤、淋巴结、转移、血液] 阶段进行调整)。 研究队列包括461名MF患者(诊断时，年龄中位数[范围]为46 [5-87] 岁；275名[59.7%]男性和186名[40.3%]女性；461名[100%]中国人)。5年整体生存率(Overall Survival, OS)为82.2%，疾病特异性生存率(Disease-Specific Survival, DSS)为83.5%，无进展生存率(Progression-Free Survival, PFS)为79.6%。各阶段5年OS率分别为：IA期95.7%，IB期93.2%，IIA期95.7%，IIB期70.1%，III期55.3%，IV期23.6%。与英国队列相比，我们的中国队列在诊断时具有较年轻的中位年龄(46岁与54岁)和较有利的5年生存率(OS，分别为82.2%与75.0%)；然而，在年龄调整后，5年生存率的差异变小 (分别为77.3%与76.4%)。Cox模型显示，预后不良的预示因素分别为：年龄超过60岁(aHR [95% CI]，2.25 [1.28-3.96]; 2.09 [1.16-3.76]; 2.27 [1.39-3.72])；TNMB分期晚期；肿瘤总体分期晚期；大细胞转化(aHR [95% CI]，2.16 [1.17-3.99]; 2.29 [1.21-4.33]; 2.21 [1.26-3.86])和乳酸脱氢酶水平升高(aHR [95% CI]，3.92 [1.64-9.36]; 4.77 [1.86-12.22]; 5.05 [2.23-11.42])。此研究队列中，生物性别和斑块病变类型与预后无关。 本回顾性队列研究对中国MF患者的发现表明，与其他国家（主要为白人）在其他研究中的患者相比，亚洲患者年轻化且5年生存率较高。预后因素与以前的研究相似，除患者性别和斑块病变类型外。

There are limited prognostic statistics and data available on survival outcomes for patients with mycosis fungoides (MF) in Asia.To determine the prognostic factors and survival outcomes of patients with MF among a cohort in China.This was a retrospective cohort study of patients with MF who received treatment at a tertiary referral center for skin lymphoma (Peking University First Hospital, Beijing, China) from August 1, 2009, to August 31, 2021. Data were analyzed from September 1, 2021, to December 31, 2022.Overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS); for prognostic factors, hazard ratios (HRs), and adjusted HRs (aHRs; adjusted for sex, age, and overall TNMB [tumor, node, metastasis, blood] stage) determined using the Cox proportional hazards model.The study cohort comprised 461 patients with MF (median [range] age at diagnosis, 46 [5-87] years; 275 [59.7%] men and 186 [40.3%] women; 461 [100%] Chinese). The overall 5-year rate was 82.2% for OS, 83.5% for DSS, and 79.6% for PFS. Stage-specific 5-year OS rates were 95.7% for stage IA, 93.2% for IB, 95.7% for IIA, 70.1% for IIB, 55.3% for III, and 23.6% for IV. Compared with a UK cohort, our Chinese cohort had a younger median age at diagnosis (46 years vs 54 years) and a more favorable 5-year OS (82.2% vs 75.0%); however, after adjusting for age, the discrepancy in the 5-year OS rate was diminished (77.3% vs 76.4%). Cox models revealed that unfavorable predictors of OS, PFS, and DSS, respectively, were: age older than 60 years (aHR [95% CI], 2.25 [1.28-3.96]; 2.09 [1.16-3.76]; 2.27 [1.39-3.72]); advanced TNMB stage; advanced overall stage; large-cell transformation (aHR [95% CI], 2.16 [1.17-3.99]; 2.29 [1.21-4.33]; 2.21 [1.26-3.86]); and elevated lactate dehydrogenase levels (aHR [95% CI], 3.92 [1.64-9.36]; 4.77 [1.86-12.22]; 5.05 [2.23-11.42]). Biological sex and plaque lesion type were not associated with prognosis among this study cohort.The findings of this retrospective cohort study of patients with MF in China suggest that Asian patients are diagnosed at a younger age and have a higher 5-year OS compared with patients of other races in studies in other countries (predominantly White). Prognostic factors were similar to those of previous studies, except for patient sex and plaque lesion type.